D-Val-Leu-Lys 4-nitroanilide dihydrochloride
Need Assistance?
  • US & Canada:
    +
  • UK: +

D-Val-Leu-Lys 4-nitroanilide dihydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

D-Val-Leu-Lys 4-nitroanilide dihydrochloride stands as a crucial substrate to gauge the efficiency of trypsin-like serine proteases. Proteolysis event leads to the release of a yellow colored product, whose quantification can be done at 405 nm. Its utility can be seen in trypsin activity detection and the evaluation of agents restricting trypsin-like proteases. Consistent usage of this product aids in experimental design and the analysis of diverse protease substrates.

Category
Others
Catalog number
BAT-014255
CAS number
62354-43-2
Molecular Formula
C23H40Cl2N6O5
Molecular Weight
551.5
D-Val-Leu-Lys 4-nitroanilide dihydrochloride
Size Price Stock Quantity
5 mg $199 In stock
IUPAC Name
(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-N-(4-nitrophenyl)hexanamide;dihydrochloride
Synonyms
(S)-6-Amino-2-((S)-2-((R)-2-amino-3-methylbutanamido)-4-methylpentanamido)-N-(4-nitrophenyl)hexanamide dihydrochloride; H-D-Val-Leu-Lys-pNA 2HCl
InChI
InChI=1S/C23H38N6O5.2ClH/c1-14(2)13-19(28-23(32)20(25)15(3)4)22(31)27-18(7-5-6-12-24)21(30)26-16-8-10-17(11-9-16)29(33)34;;/h8-11,14-15,18-20H,5-7,12-13,24-25H2,1-4H3,(H,26,30)(H,27,31)(H,28,32);2*1H/t18-,19-,20+;;/m0../s1
InChI Key
VESQMNNSPPEOSZ-ZLARAOTRSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CCCCN)C(=O)NC1=CC=C(C=C1)[N+](=O)[O-])NC(=O)C(C(C)C)N.Cl.Cl
1. A Modified ELISA Method to Evaluate the Interaction of Schistosoma mansoni Proteins with Plasminogen
Luis G V Fernandes, Rafaela S Fernandes, Ana L T O Nascimento, Luciana C C Leite Methods Mol Biol. 2020;2151:185-195. doi: 10.1007/978-1-0716-0635-3_15.
An important aspect of host-pathogen interactions is the interference of secreted proteins with the fibrinolytic system. Herein, we describe a modified ELISA method used to evaluate the interaction of a recombinant Schistosoma mansoni protein with plasminogen (PLG). Using this protocol, we demonstrated that a secreted protein, recombinant venom allergen-like protein 18 (rSmVAL18) acts as a plasminogen receptor increasing its activation into plasmin in the presence of the urokinase-type plasminogen activator (uPA). PLG binding was determined by immobilizing human PLG in the plate and incubating with the recombinant protein; competitive binding with a lysine analog demonstrated the interaction of the protein lysine residues with PLG Kringle domains. To assess the activation of S. mansoni recombinant protein-bound PLG, the amidolytic activity of generated plasmin was measured using the D-Val-Leu-Lys 4-nitroanilide dihydrochloride substrate.
2. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates
G L Hortin, B L Trimpe J Biol Chem. 1991 Apr 15;266(11):6866-71.
Acidic synthetic peptides corresponding to segments of several nonhomologous proteins (hirudin, residues 54-65; heparin cofactor II, residues 54-75; and fibrinogen, residues 410-427 of the gamma B-chain) inhibit thrombin's cleavage of fibrinogen without blocking the enzyme's active site. Here, we examined effects of these peptides on thrombin's cleavage of protein C and small peptides. Activation of protein C by thrombin in the absence of calcium was inhibited by all of the peptides. Maximal inhibition was 60%, and no greater inhibition was produced by higher peptide concentrations. This differed from progressive inhibition of protein C activation by increasing peptide concentrations in the presence of thrombomodulin and calcium. Potencies of the peptides were in the order hirudin-(54-65) greater than heparin cofactor II-(54-75) greater than gamma B-chain-(410-427). Sulfation of the tyrosine residue in hirudin-(54-65) increased its potency about 10-fold, similar to changes in anticlotting activity. The peptides were activators rather than inhibitors of the cleavage of small chromogenic substrates. In the presence of the peptides, the affinity of thrombin for the substrates S-2366 (pyro-Glu-Pro-Arg-4-nitroanilide), Chromozyme TH (tosyl-Gly-Pro-Arg-4-nitroanilide), and S-2251 (D-Val-Leu-Lys-4-nitroanilide) increased 1.5-2-fold with little change in the Vmax of substrate cleavage. Potencies of peptides in these allosteric effects on thrombin was in the same order as for their other effects. The similar actions of these nonhomologous peptides, which are believed to bind to thrombin's anion-binding exosite, suggest that binding of any peptide to this site exerts the same allosteric effect on thrombin's active site. Interactions of these peptides with thrombin may serve as models for regulation of thrombin's interactions with natural substrates and inhibitors.
3. In vitro identification of novel plasminogen-binding receptors of the pathogen Leptospira interrogans
Monica L Vieira, Marina V Atzingen, Tatiane R Oliveira, Rosane Oliveira, Daniel M Andrade, Silvio A Vasconcellos, Ana L T O Nascimento PLoS One. 2010 Jun 22;5(6):e11259. doi: 10.1371/journal.pone.0011259.
Background: Leptospirosis is a multisystem disease caused by pathogenic strains of the genus Leptospira. We have reported that Leptospira are able to bind plasminogen (PLG), to generate active plasmin in the presence of activator, and to degrade purified extracellular matrix fibronectin. Methodology/principal findings: We have now cloned, expressed and purified 14 leptospiral recombinant proteins. The proteins were confirmed to be surface exposed by immunofluorescence microscopy and were evaluated for their ability to bind plasminogen (PLG). We identified eight as PLG-binding proteins, including the major outer membrane protein LipL32, the previously published rLIC12730, rLIC10494, Lp29, Lp49, LipL40 and MPL36, and one novel leptospiral protein, rLIC12238. Bound PLG could be converted to plasmin by the addition of urokinase-type PLG activator (uPA), showing specific proteolytic activity, as assessed by its reaction with the chromogenic plasmin substrate, D-Val-Leu-Lys 4-nitroanilide dihydrochloride. The addition of the lysine analog 6-aminocaproic acid (ACA) inhibited the protein-PLG interaction, thus strongly suggesting the involvement of lysine residues in plasminogen binding. The binding of leptospiral surface proteins to PLG was specific, dose-dependent and saturable. PLG and collagen type IV competed with LipL32 protein for the same binding site, whereas separate binding sites were observed for plasma fibronectin. Conclusions/significance: PLG-binding/activation through the proteins/receptors on the surface of Leptospira could help the bacteria to specifically overcome tissue barriers, facilitating its spread throughout the host.
Online Inquiry
Verification code
Inquiry Basket